The FTC Has the Chance to Rein in Big Pharma

Semaglutide manufacturers seem to be taking advantage of America’s health crises to indulge in anticompetitive behavior.

The Background Check Game Changer: Meet Searqle
- Why Superman Returns Failed - Drew Dietsch
- Inside ‘Operation Narnia,’ the Daring Attack Israel Feared It Couldn’t Pull Off - MeighTimbol
- Trump administration may cut funds to hospitals offering gender care to kids
- Hundreds of Brother printer models have security flaw that can't be patched - Lawrence Bonk
- Google Launches Accelerate with Google Resource Hub for Advertisers - Michael Terry
- The shortest day ever recorded could occur this summer

The Risk of (Individual) Stocks
- Protecting Your Business from AI-Enabled Cyber Threats - GFMag.com Admin
- They Couldn't Have Picked A Worse Time To Announce The Stand Movie - Drew Dietsch
- 15 Early Amazon Prime Day Deals on Our Favorite Walking Shoes We Tested—Up to 61% Off - Lauren Paige Richeson
- Mexican Navy Brooklyn Bridge Crash Gets Weirder—Why Was It Going Backwards?
- The Future of Healthcare: The AI-Powered Smart Aid Kit - Michael A. Medeiros
- Armed woman camped out on road after traffic crash closes Houston highway